Ifupinostat (trade name Betlin) is a drug used for the treatment of cancer. It is approved in China for adults with relapsed or refractory diffuse large B-cell lymphoma who have received at least two lines of systemic therapy.[1] It is being developed by BeBetter Med.[2]
Ifupinostat acts as both a phosphoinositide 3-kinase α (PI3Kα) inhibitor and a histone deacetylase (HDAC) inhibitor.[1][3][4]
References
- ^ a b Fung S (December 2025). "Ifupinostat: First Approval". Drugs. 85 (12): 1629–1633. doi:10.1007/s40265-025-02248-z. PMID 41028651.
- ^ "Ifupinostat - BeBetter Med". AdisInsight. Springer Nature Switzerland AG.
- ^ Wang N, Mo Z, Pan L, Zhou M, Ye X, Liu X, et al. (November 2023). "Dual PI3K/HDAC Inhibitor BEBT-908 Exhibits Potent Efficacy as Monotherapy for Primary Central Nervous System Lymphoma". Targeted Oncology. 18 (6): 941–952. doi:10.1007/s11523-023-01006-z. PMID 37855991.
- ^ Luzietti L, Pires GS, Ryan A, Regidor C, Hiller M, Sarti D, et al. (2025). "Design, synthesis, and biological evaluation of novel triazine-based dual HDAC/PI3K inhibitors for breast cancer therapy". ChemRxiv. doi:10.26434/chemrxiv-2025-tzwbz.